Cost-effectiveness acceptability curves using WTP thresholds for each strategy in patients with primary refractory/early relapsed DLBCL. The blue curve represents the percent iterations second-line CAR-T is the cost-effective strategy at each WTP threshold. In contrast, the red curve represents the percent iterations that second-line CAR-T is no longer the cost-effective strategy.